The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Open accessAbstract
BACKGROUND: Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy and a proposed substrate for arrhythmias and heart failure. In animal models, profibrotic genetic pathways are activated early, before hypertrophic remodeling. Data showing early profibrotic responses to sarcomere-gene mutations in patients with hypertrophic cardiomyopathy are lacking. METHODS: We used echocardiography, cardiac magnetic resonance imaging (MRI), and serum biomarkers of collagen metabolism, hemodynamic stress, and myocardial injury to evaluate subjects with hypertrophic cardiomyopathy and a confirmed genotype. RESULTS: The study involved 38 subjects with pathogenic sarcomere mutations and overt hypertrophic cardiomyopathy, 39 subjects with mutations but no left ventricular hypertrophy, and 30 controls who did not have mutations. Levels of serum C-terminal propeptide of type I procollagen (PICP) were significantly higher in mutation carriers without left ventricular hypertrophy and in subjects with overt hypertrophic cardiomyopathy than in controls (31% and 69% higher, respectively; P<0.001). The ratio of PICP to C-terminal telopeptide of type I collagen was increased only in subjects with overt hypertrophic cardiomyopathy, suggesting that collagen synthesis exceeds degradation. Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibrosis, in 71% of subjects with overt hypertrophic cardiomyopathy but in none of the mutation carriers without left ventricular hypertrophy. CONCLUSIONS: Elevated levels of serum PICP indicated increased myocardial collagen synthesis in sarcomere-mutation carriers without overt disease. This profibrotic state preceded the development of left ventricular hypertrophy or fibrosis visible on MRI. (Funded by the National Institutes of Health and others.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Ommen, S. R., Nishimura, R. A., Appleton, C. P., Miller, F. A., Oh, J. K., Redfield, M. M., & Tajik, A. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1788 · Cited by 2,790
Kim, R. J., Fieno, D. S., Parrish, T. B., Harris, K., Chen, E.-L., Simonetti, O., Bundy, J., Finn, J. P., Klocke, F. J., & Judd, R. M. (1999) · Circulation · doi:10.1161/01.cir.100.19.1992 · Cited by 2,581
Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995) · Circulation · doi:10.1161/01.cir.92.4.785 · Cited by 2,275
Coronary Microvascular Dysfunction
Camici, P. G., & Crea, F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra061889 · Cited by 1,605
Coronary Microvascular Dysfunction
Crea, F., Lanza, G. A., & Camici, P. G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5367-0 · Cited by 1,287
Grothues, F., Smith, G. C., Moon, J. C. C., Bellenger, N. G., Collins, P., Klein, H. U., & Pennell, D. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02381-0 · Cited by 1,267
The Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046
Self-citationZannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 947
Moon, J. C. C., McKenna, W. J., McCrohon, J. A., Elliott, P. M., Smith, G. C., & Pennell, D. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00189-x · Cited by 766
Cited by
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
Self-citationHypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
Self-citationMaron, B. J., & Maron, M. S. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60397-3 · Cited by 1,231
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Clinical Course and Management of Hypertrophic Cardiomyopathy
Maron, B. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1710575 · Cited by 944
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.003 · Cited by 652
Watkins, H., Ashrafian, H., & Redwood, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0902923 · Cited by 496
Puntmann, V. O., Voigt, T., Chen, Z., Mayr, M., Karim, R., Rhode, K., Pastor, A., Carr-White, G., Razavi, R., Schaeffter, T., et al. (2013) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2012.08.019 · Cited by 487
Genetic mutations and mechanisms in dilated cardiomyopathy
McNally, E. M., Golbus, J. R., & Puckelwartz, M. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62862 · Cited by 478
Pelliccia, A., Solberg, E. E., Papadakis, M., Adami, P. E., Biffi, A., Caselli, S., La Gerche, A., Niebauer, J., Pressler, A., Schmied, C. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy730 · Cited by 442
Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity
Richards, D. J., Li, Y., Kerr, C. M., Yao, J., Beeson, G. C., Coyle, R. C., Chen, X., Jia, J., Damon, B., Wilson, R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0539-4 · Cited by 439
Extracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Lipshultz, S. E., Law, Y. M., Asante-Korang, A., Austin, E. D., Dipchand, A. I., Everitt, M. D., Hsu, D. T., Lin, K. Y., Price, J. F., Wilkinson, J. D., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000682 · Cited by 416
Self-citationEvaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Ho, C. Y., Mealiffe, M. E., Bach, R. G., Bhattacharya, M., Choudhury, L., Edelberg, J. M., Hegde, S. M., Jacoby, D., Lakdawala, N. K., Lester, S. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.064 · Cited by 355
Self-citationOlivotto, I., Cecchi, F., Poggesi, C., & Yacoub, M. H. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.967026 · Cited by 352
Dass, S., Suttie, J. J., Piechnik, S. K., Ferreira, V. M., Holloway, C. J., Banerjee, R., Mahmod, M., Cochlin, L., Karamitsos, T. D., Robson, M. D., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.976738 · Cited by 348
Transforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review
Puntmann, V. O., Peker, E., Chandrashekhar, Y., & Nagel, E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307974 · Cited by 337
Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy
Burke, M. A., Cook, S. A., Seidman, J. G., & Seidman, C. E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.079 · Cited by 325
Self-citation2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.020 · Cited by 322
Self-citationCardim, N., Galderisi, M., Edvardsen, T., Plein, S., Popescu, B. A., D'Andrea, A., Bruder, O., Cosyns, B., Davin, L., Donal, E., et al. (2015) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jeu291 · Cited by 284
Ho, C. Y., Abbasi, S. A., Neilan, T. G., Shah, R. V., Chen, Y., Heydari, B., Cirino, A. L., Lakdawala, N. K., Orav, E. J., González, A., et al. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.000333 · Cited by 260
Self-citationHypertrophic obstructive cardiomyopathy
Veselka, J., Anavekar, N. S., & Charron, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31321-6 · Cited by 257
Emerging Biomarkers in Heart Failure
van Kimmenade, R. R. J., & Januzzi, J. L. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.165720 · Cited by 257
Hinojar, R., Varma, N., Child, N., Goodman, B., Jabbour, A., Yu, C.-Y., Gebker, R., Doltra, A., Kelle, S., Khan, S., et al. (2015) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.115.003285 · Cited by 254
Mechanisms of disease: hypertrophic cardiomyopathy
Frey, N., Luedde, M., & Katus, H. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.159 · Cited by 235
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017) · ERJ Open Research · doi:10.1183/23120541.00074-2016 · Cited by 139
van Dijk, S. J., Paalberends, E. R., Najafi, A., Michels, M., Sadayappan, S., Carrier, L., Boontje, N. M., Kuster, D. W. D., van Slegtenhorst, M., Dooijes, D., et al. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.963702 · Cited by 124
Cell-cell interaction in the heart via Wnt/ -catenin pathway after cardiac injury
Deb, A. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu054 · Cited by 102
Prasad, V., Jorgenson, J., Ioannidis, J. P. A., & Cifu, A. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.11.005 · Cited by 90
Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79
Cardiac Fibroblasts and the Extracellular Matrix in Regenerative and Nonregenerative Hearts
Hortells, L., Johansen, A. K. Z., & Yutzey, K. E. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030029 · Cited by 79
Wang, L., Wang, Y., Wang, J., Xiao, M., Xi, X.-Y., Chen, B.-X., Su, Y., Zhang, Y., Xie, B., Dong, Z., et al. (2023) · Radiology · doi:10.1148/radiol.221052 · Cited by 73
van Velzen, H. G., Vriesendorp, P. A., Oldenburg, R. A., van Slegtenhorst, M. A., van der Velden, J., Schinkel, A. F. L., & Michels, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.038 · Cited by 46
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.04.018 · Cited by 42
Self-citationCardiovascular health and outcomes in carriers with genetic variants of hypertrophic cardiomyopathy
Patel, N., Gaonkar, M., Pampana, A., Dhaliwal, J. S., Vekariya, N., Shetty, N. S., Li, P., Kalra, R., Arora, G., & Arora, P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.12.018 · Cited by 2
Metadata
- Authors
- Ho, C. Y., López, B., Coelho-Filho, O. R., Lakdawala, N. K., Cirino, A. L., Jarolim, P., Kwong, R., González, A., Colan, S. D., Seidman, J. G., Díez, J., & Seidman, C. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-05
- Volume
- 363
- Issue
- 6
- Pages
- 552-563
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2130120331
- Cited by
- 696
- References
- 45
- FWCI
- 27.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.